SEHK:6990Biotechs
A Look At Sichuan Kelun Biotech (SEHK:6990) Valuation After SKB103 IND Approval And Pipeline Progress
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just received Chinese regulator approval for its SKB103 IND in advanced solid tumors, marking a new clinical milestone that comes alongside recent earnings and oncology trial updates.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The regulatory green light for SKB103 comes after a series of oncology updates and full-year 2025 results. The share price has reacted, with a 7.07% 1-day share price return and 18.12% 30-day...